Journals / Turkish Journal of Gastroenterology / 2013 / Cilt: 24 - Sayı: 1

Azithromycin based triple therapy versus standard clarithromycin based triple therapy in eradication of Helicobacter pylori infection in Iran: a randomized controlled clinical trial

‹ran'da Helikobakter pilori enfeksiyonunun eradikasyonunda azitromisin bazlı üçlü tedavi ile standart klaritromisin tabanlı üçlü tedavinin karşılaştırılması: randomize kontrollü klinik çalışma

Pages
10–14
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: The results of this study suggest that azithromycin, amoxicillin, and omeprazole at best is as effective as clarithromycin, amoxicillin, and omeprazole; and this new therapy could be considered as an alternative choice for Helicobacter pylori eradication, especially in geographic areas with lower economic status.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aims: In regarding to azithromycin’s high tissue concentration, long biologic half life, low cost, and excellent anti bacterialprofile for Helicobacter pylori in Iran, we sought to compare an azithromycin-based regimen with an already established clarithromycinbased regimen in regards to the eradication of Helicobacter pylori infection.
📊
Key Findings & Data:Material and Methods: A prospective, open label, randomizedcontrolled trial was conducted on 165 patients who presented to gastrointestinal clinics of QOM Medical University Clinics, with complaintof dyspepsia.
💡
Conclusion & Impact:Conclusion: The results of this study suggest that azithromycin, amoxicillin, and omeprazole at best is as effective as clarithromycin, amoxicillin, and omeprazole; and this new therapy could be considered as an alternative choice for Helicobacter pylori eradication, especially in geographic areas with lower economic status.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background/aims: In regarding to azithromycin’s high tissue concentration, long biologic half life, low cost, and excellent anti bacterialprofile for Helicobacter pylori in Iran, we sought to compare an azithromycin-based regimen with an already established clarithromycinbased regimen in regards to the eradication of Helicobacter pylori infection. Material and Methods: A prospective, open label, randomizedcontrolled trial was conducted on 165 patients who presented to gastrointestinal clinics of QOM Medical University Clinics, with complaintof dyspepsia. All patients received upper gastrointestinal endoscopy, and underwent rapid urease test to confirm Helicobacter pylori infection. Patients were randomized to a treatment arm, which consisted of, clarithromycin, amoxicillin, and omeprazole, or another treatmentarm consisting of azithromycin, amoxicillin, and omeprazole. Informed consent was obtained from all patients participating in the trial.Urease breath test was performed in patients 6 weeks after end of treatment to assess eradication. All side effects were recorded. Comparisonbetween the two groups was made using a chi-square test. Result: Seventy six and 89 patients received regimen clarithromycin, amoxicillin,and omeprazole and azithromycin, amoxicillin, and omeprazole, respectively, and completed the study course. Per protocol, eradication ratewas 83% with clarithromycin, amoxicillin, and omeprazole and 75% with azithromycin, amoxicillin, and omeprazole (p =0.158). Eradicationrate for a subgroup of patients with peptic ulcer disease in two groups were 83% and 74%, respectively (p=0.134). Only one patient in eachgroup was compelled to stop the treatment due to a severe skin hypersensitivity reaction. Other lesser side effects were comparable within thetwo groups. Conclusion: The results of this study suggest that azithromycin, amoxicillin, and omeprazole at best is as effective as clarithromycin, amoxicillin, and omeprazole; and this new therapy could be considered as an alternative choice for Helicobacter pylori eradication, especially in geographic areas with lower economic status.

Özet

Amaç: Yüksek doku konsantrasyonu, uzun biyolojik yar› ömrü, mükemmel antibakteriyel profili ve ‹ran'daki düflük maliyeti nedeniyle, Helikobakter pilori infeksiyonu eradikasyonunda azitromisin bazl› rejim ile halen kullan›lan klaritromisin bazl› rejimin karfl›laflt›r›lmas›n› amaçlad›k. Gereç ve Yöntem: QOM T›p Fakültesi Gastroenteroloji Klini¤i’ne dispepsi nedeniyle baflvuran 165 hastada prospektif aç›k etiketli randomize kontrollü bir çal›flma yap›ld›. Bütün hastalara üst gastrointestinal sistem endoskopisi ve Helikobakter pilori infeksiyonunun konfirmasyonu için h›zl› üreaz testi yap›ld›. Hastalar klaritromisin, amoksisilin ve omeprazol'den oluflan bir tedavi kolu ve azitromisin, amoksisilin ve omeprazol'den oluflan bir di¤er kola randomize edildi. Çal›flmaya kat›lan bütün hastalardan ayd›nlat›lm›fl onam al›nd›. Hastalara tedaviden 6 hafta sonra eradikasyonu test etmek için üreaz nefes testi yap›ld›. Bütün yan etkiler kaydedildi. ‹ki grup aras›ndaki karfl›laflt›rmalar ki-kare testiyle yap›ld›. Bulgular: Çal›flmay› klaritromisin, amoksisilin ve omeprazol ve azitromisin, amoksisilin ve omeprazol gruplar›nda s›ras›yla 26 ve 89 hasta tamamlad›. Per protokol eradikasyon oran› klaritromisin, amoksisilin ve omeprazol ile %83 ve azitromisin, amoksisilin ve omeprazol ile %75 idi. ‹ki grupta peptik ülseri olan hastalardaki eradikasyon oran› s›ras›yla %83 ve %74 idi (p=0.134). Her iki gruptan birer hastada ciltte ciddi hipersenstivite reaksiyonu nedeniyle ilaç kesilmesi gerekti. ‹ki grupta daha az ciddi yan etkiler aras›nda fark yoktu. Sonuç: Bu çal›flman›n sonuçlar›na göre azitromisin, amoksisilin ve omeprazol, klaritromisin, amoksisilin ve omeprazol kadar etkindir ve özellikle düflük ekonomik düzeyli co¤rafi bölgelerde Helikobakter pilori eradikasyon tedavisi için alternatif bir seçim olarak düflünülmelidir.

🔖

Cite This Article

IRANIKHAH, A., SARKESHIKIAN, S. S., GHADIR, M. R. (2022). Azithromycin based triple therapy versus standard clarithromycin based triple therapy in eradication of Helicobacter pylori infection in Iran: a randomized controlled clinical trial. Turkish Journal of Gastroenterology, Cilt: 24 - Sayı: 1, 10–14. https://ajindex.com/articles/606290

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Sullivan B, Coyle W, Nemec R, Dunteman T. Comparison of azithromycin and clarithromycin in triple therapy regimens for the eradication of Helicobacter pylori. Am J Gastroenterol 2002;97:2536-9
  2. Lacy BE, Rosemore J. Helicobacter pylori: ulcers and more: the beginning of an era. J Nutr 2001;131:2789S-93S
  3. Thomson AB, Barkun AN, Armstrong D, et al. The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment-Prompt Endoscopy (CADET-PE) study [Published correction appears in Aliment Pharmacol Ther 2004;20:702]. Aliment Pharmacol Ther 2003;17:1481-91
  4. Everhart JE. Recent developments in the epidemiology of Helicobacter pylori. Gastroenterol Clin North Am 2000;29: 559-78
  5. Gold BD, Colletti RB, Abbott M, et al and North American Society for Pediatric Gastroenterology and Nutrition. Helicobacter pylori infection in children: recommendations for diagnosis and treatment. J Pediatr Gastroenterol Nutr 2000;31:490-7
  6. Staat MA, Kruszon-Moran D, McQuillan GM, Kaslow RA. A population-based serologic survey of Helicobacter pylori infection in children and adolescents in the United States. J Infect Dis 1996;174:1120-3
  7. Unge P, Berstad A. Pooled analysis of anti-Helicobacter pylori treatment regimens. Scand J Gastroentrol Suppl. 1996;220:27-40
  8. Sepulveda AR, Graham DY. Role of Helicobacter pylori in gastric carcinogenesis. Gastroenterol Clin North Am 2002;31:517-35
  9. Hunt RH. Will eradication of Helicobacter pylori infection influence the risk of gastric cancer? Am J Med 2004;117 (Suppl 5A):86S-91S
  10. Gisbert JP, Khorrami S, Carballo F, et al. H. pylori eradication therapy vs. antisecretory non-eradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. Cochrane Database Syst Rev 2004;CD004062 11. Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroen- terol 2004;99:1833-55
  11. Laine L, Schoenfeld P, Fennerty MB. Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta- analysis of randomized, controlled trials. Ann Intern Med 2001;134:361-9
  12. Coelho LGV, Mattos AA, Francisconi CFM, et al. Efficacy of the dosing regimen of pantoprazole 40 mg, amoxicillin 1000 mg and clarithromycin 500 mg, twice daily for 7 days, in the eradicati